Biochemistry and Molecular Biology Unit, Department of Biology, University of Girona, 17003 Girona, Spain.
Pathology Department, Josep Trueta University Hospital, 17007 Girona, Spain.
J Proteomics. 2021 Jan 16;231:104004. doi: 10.1016/j.jprot.2020.104004. Epub 2020 Oct 7.
Late diagnosis of pancreatic ductal adenocarcinoma (PDA) is one of the reasons of its low 5-year survival rate and it is due to its unspecific symptoms during the first stages of the disease and the lack of reliable serological markers. Since PDA shows an altered glycan expression, here we have focused on finding novel potential biomarkers, namely glycoproteins that express the tumor associated carbohydrate structure sialyl-Lewis x (sLe), which is described in PDA. Through a glycoproteomic approach, we have analyzed target proteins containing sLe from PDA tissues by 2DE and immunodetection techniques, and have identified by mass spectrometry the protein MFAP4 as a carrier of sLe in PDA. MFAP4 showed a higher expression in PDA tissues compared with pancreatic control tissues. In addition, the colocalization of sLe over MFAP4 was found only in PDA and not in control pancreatic tissues. The analysis of MFAP4 expression in PDA cell lines and their secretome, in combination with immunohistochemistry of pancreatic tissues, revealed that MFAP4 was not produced by PDA cells, but it was found in the pancreatic extracellular matrix. The specificity of MFAP4 glycoform containing sLe in PDA tissues shows its relevance as a potential PDA biomarker. SIGNIFICANCE: Despite advances in the field of cancer research, pancreatic ductal adenocarcinoma (PDA) lacks of a specific and sensitive biomarker for its early detection, when curative resection is still possible before metastases arise. Thus, efforts to discover new PDA biomarkers represent the first line in the fight against the increase of its incidence reported in recent years. Glycan alterations on glycoconjugates, such as glycoproteins have emerged as a rich source for the identification of novel cancer markers. In the present work, we aimed to shed light on novel biomarkers based on altered glycosylation in PDA, in particular those glycoproteins of PDA tissues carrying the tumor carbohydrate antigen sialyl-Lewis x (sLe). Through a glycoproteomic approach, we have shown that the glycoprotein MFAP4 carries sLe in PDA tissues and not in control pancreatic tissues. MFAP4 is found in the extracellular matrix in PDA and although its role in cancer progression is unclear, its sLe glycoform could be a potential biomarker in pancreatic ductal adenocarcinoma.
胰腺导管腺癌 (PDA) 诊断较晚是其 5 年生存率低的原因之一,这是由于其在疾病早期阶段症状不特异,且缺乏可靠的血清标志物。由于 PDA 表现出糖基化表达的改变,因此我们专注于寻找新的潜在生物标志物,即表达肿瘤相关碳水化合物结构唾液酸化-Lewis x (sLe) 的糖蛋白,该结构在 PDA 中已有描述。通过糖蛋白质组学方法,我们通过 2DE 和免疫检测技术分析了来自 PDA 组织的含有 sLe 的靶蛋白,并通过质谱鉴定出 MFAP4 蛋白作为 PDA 中 sLe 的载体。MFAP4 在 PDA 组织中的表达高于胰腺对照组织。此外,仅在 PDA 中发现 sLe 与 MFAP4 的共定位,而在对照胰腺组织中未发现。在 PDA 细胞系及其分泌组中分析 MFAP4 的表达,并结合胰腺组织的免疫组织化学分析表明,MFAP4 不是由 PDA 细胞产生的,而是在胰腺细胞外基质中发现的。在 PDA 组织中含有 sLe 的 MFAP4 糖型的特异性表明其作为潜在 PDA 生物标志物的相关性。意义:尽管在癌症研究领域取得了进展,但胰腺导管腺癌 (PDA) 缺乏用于早期检测的特异性和敏感的生物标志物,而在转移发生之前仍然可以进行治愈性切除。因此,发现新的 PDA 生物标志物的努力代表了对抗近年来报道的发病率增加的第一战线。糖缀合物(如糖蛋白)上的聚糖改变已成为鉴定新的癌症标志物的丰富来源。在本工作中,我们旨在阐明基于 PDA 中糖基化改变的新型生物标志物,特别是那些携带肿瘤碳水化合物抗原唾液酸化-Lewis x (sLe) 的 PDA 组织糖蛋白。通过糖蛋白质组学方法,我们表明糖蛋白 MFAP4 在 PDA 组织中携带 sLe,而在对照胰腺组织中不携带。MFAP4 存在于 PDA 的细胞外基质中,尽管其在癌症进展中的作用尚不清楚,但它的 sLe 糖型可能是胰腺导管腺癌的潜在生物标志物。